Furthermore, integrating scRNA sequencing with multi-omics bioinformatics of TCGA and GTEx data, this study identifies ARHGEF12 as a key regulator of cisplatin resistance in BLCA for the first time, opening new avenues and potential targets for elucidating mechanisms of cisplatin resistance in bladder cancer. Here, ARHGEF12 is linked to urinary bladder cancer.